Literature DB >> 19914456

Lentigo maligna: diagnosis and treatment.

Mark W Bosbous1, William W Dzwierzynski, Marcelle Neuburg.   

Abstract

Lentigo maligna is an overgrowth of atypical melanocytes at the dermal-epidermal junction also known as melanoma in situ. Left untreated, these lesions can continue to grow, resulting in dermal invasion and progression to lentigo maligna melanoma. Many operative and nonoperative treatments have been developed with the goals of preserving function and cosmesis while at the same time addressing the diffuse nature of these lesions. Previous recommendations have led plastic surgeons to commonly perform wide local excision with 5 mm margins. More recent literature has suggested that in many cases this treatment can result in high recurrence rates. This has led to margin control procedures becoming the treatment of choice for these lesions.

Entities:  

Mesh:

Year:  2010        PMID: 19914456     DOI: 10.1016/j.cps.2009.08.006

Source DB:  PubMed          Journal:  Clin Plast Surg        ISSN: 0094-1298            Impact factor:   2.017


  3 in total

1.  Practical application of laser reflectance confocal microscopy in the follow-up of patients with lentigo maligna undergoing treatment with Imiquimod.

Authors:  Priscila Ishioka; Lilian Lemos Costa; Marcus Maia
Journal:  An Bras Dermatol       Date:  2022-06-09       Impact factor: 2.113

2.  Hyperspectral Imaging Reveals Spectral Differences and Can Distinguish Malignant Melanoma from Pigmented Basal Cell Carcinomas: A Pilot Study.

Authors:  Janne Räsänen; Mari Salmivuori; Ilkka Pölönen; Mari Grönroos; Noora Neittaanmäki
Journal:  Acta Derm Venereol       Date:  2021-02-19       Impact factor: 3.875

Review 3.  Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.

Authors:  Jean Christopher Chamcheu; Tithi Roy; Mohammad Burhan Uddin; Sergette Banang-Mbeumi; Roxane-Cherille N Chamcheu; Anthony L Walker; Yong-Yu Liu; Shile Huang
Journal:  Cells       Date:  2019-07-31       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.